SYN115 (Tozadenant) is a orally-available, benzothiazole-based, antagonist of the Adenosine A2A receptor for the treatment of Parkinson's disease and other CNS-related conditions. SYN115 is being pursued as a monotherapy as well as in combination with L-dopamine and is being studied for its potential neuroprotective effects. [1]

Animal studies with SYN115 support beliefs that A2A antagonists reduce Parkinson's symptoms by reducing the inhibitory output of the basal ganglia indirect pathway. Using Cerebral Blood Flow (CBF) as a pharmacodynamic parameter, studies have shown that SYN115 induces a significant decrease in thalamic CBF, consistent with the deactivation of the indirect pathway. [2]